<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/shutterstock_2260036901-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/02/shutterstock_2260036901-430x241.jpg"/>
                                    
                                    <figcaption>Kyowa Kirin will regain control of the global programme for rocatinlimab in AD as Amgen terminates development and commercialisation agreement. Image credit: Antonina Vlasova via ShutterStock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Amgen is handing back the rights of its successful in-licensed atopic dermatitis (AD) asset, rocatinlimab, to Kyowa Kirin.</p>



<p>In a statement to <em>Pharmaceutical Technology</em>, an Amgen spokesperson noted that this move was part of its “ongoing portfolio prioritisation process”, which will see the company transfer responsibility for the rocatinlimab programme back to its original developer.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>As Amgen relinquishes its stake in the anti-OX40 monoclonal antibody (mAb), Kyowa will now take full responsibility for the drug’s further development, as well as future regulatory submissions and commercialisation efforts involving the OX40 receptor agonist. The Tokyo-based pharma plans to submit rocatinlimab to regulators for AD in H1 2026.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>If rocatinlimab gets the regulatory go-ahead, Kyowa plans to “commercialise the drug through a flexible, market-by-market approach, starting in the US”, the company’s president and COO, Abdul Mullick tells<em> Pharmaceutical Technology</em>.</p>



<p>Mullick said: “Kyowa Kirin is confident in the potential of rocatinlimab to address critical unmet needs for patients with moderate-to-severe AD, who are looking for new long-lasting options that may address the chronic nature of unpredictable flares. Rocatinlimab’s science and its highly differentiated mechanism of action targeting the OX40 receptor make it a potentially unique treatment option.”</p>



<p>A patient-based forecast from GlobalData estimates that rocatinlimab will generate 2033 global sales of $1.7bn in AD.</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<h2 id="h-the-ox40-ligand-s-role-in-ad">The OX40 ligand’s role in AD</h2>



<p>Once touted as one of the most promising new targets in AD, analyst excitement around the OX40 drug class has taken a hit as trial data have failed to meet expectations. This comes as recent late-stage efficacy and safety readouts for both rocatinlimab and Sanofi’s rival OX40 candidate, amlitelimab, garnered lukewarm responses.</p>



<p>During the Phase III ROCKET-IGNITE, ROCKET-HORIZON and ASCEND trials of rocatinlimab, the drug met all its co-primary and secondary endpoints, but efficacy results generally fell short of analyst expectations.</p><div id="slot-two"></div>



<p>It was a similar outcome for amlitelimab, which did not live up to the legacy of Sanofi and Regeneron’s best-selling AD drug, Dupixent (dupilumab), leading GlobalData analysts to theorise that the drug will see most uptake in the second- or third-line setting.</p>



<p>In the Phase II ATLANTIS trial (NCT05769777) in AD, treatment with amlitelimab also triggered a cutaneous case of Kaposi’s sarcoma – a rare vascular cancer linked to OX40 deficiency – in a patient with known risk factors. In a research note, William Blair analyst Matt Phipps noted that this finding “could be a real safety risk for the OX40 class”.</p>



<p>However, Mullick believes that the mechanistic differences between OX40 ligand (amlitelimab) and OX40 receptors’ (rocatinlimab)-targeting approaches mean that “findings for one should not predict outcomes for the other”.</p>



<h2 id="h-unmet-needs-in-ad">Unmet needs in AD</h2>



<p>In recent years, biologics have triggered a fundamental shift in the AD treatment landscape, with therapies like Dupixent offering patients significant symptomatic relief while showing some disease-modifying potential.</p>



<p>Despite these advancements, Mullick cautions that a large number of patients do not achieve optimal treatment targets. “More than 50% of patients receiving systemics discontinue within the first year, highlighting the remaining need for options that provide more long-term control of the disease,” he said.</p>



<p>According to Mullick, rocatinlimab’s differentiated mechanism of action makes it “unique”, with its potential as a treatment option expanding across a range of clinical scenarios.</p>



<p>A recent report from GlobalData, parent company of <em>Pharmaceutical Technology</em>, forecasts that the AD market will be worth $22.4bn across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) by 2033.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

<p>Amgen has returned the rights of the eczema drug rocatinlimab to Kyowa Kirin, despite positive late-stage data. This decision is part of Amgen's portfolio prioritization process. Kyowa Kirin plans to file for US approval in atopic dermatitis by H1 2026 and aims to commercialize the drug in the US first. While rocatinlimab met its trial endpoints, analyst excitement has waned due to mixed efficacy results compared to expectations. The AD market is projected to reach $22.4 billion by 2033, highlighting ongoing unmet needs in treatment options.</p>

Pharmaceutical Technology

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

VG Health

ALPS Medical Breakthrough

Amgen

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

iShares US Pharma

Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data